Thomas A. Armer, Ph.D., Chief Scientific Officer, founded MAP Pharmaceuticals in 2003. Between 1998 and 2003, Dr. Armer served as Vice President of Pulmonary Delivery Systems and later as Chief Scientific Officer at Sheffield Pharmaceuticals, a pharmaceutical company. During his time at Sheffield, Dr. Armer was instrumental in conceiving and developing the Unit Dose Budesonide (UDB) and TempoT inhaler product lines. From 1989 to 1998, Dr. Armer held a series of senior management and product development positions at the Novon Products Group, a division of Warner-Lambert, and Aeroquip Vickers Corporation, where he and his group developed the TempoT delivery system. Dr. Armer graduated from Tulane University with a Ph.D. in chemical engineering.
Scott W. Borland, Senior Director of CNS Programs and Technical Operations, brings more than 12 years of product development and operations experience to MAP. Prior to joining the company, he held several key management positions at Capnia Inc. and Aerogen Inc., including Vice President of Engineering and Senior Director, Engineering and Operations. In these roles, Mr. Borland was responsible for engineering and manufacturing of technology components and systems for aerosol-based pulmonary drug delivery and medical gas delivery products. Mr. Borland has held several other positions in the medical device, drug delivery, and computer hardware industries with Therics, Inc., Topaz Technologies, and Applied Magnetics and was previously a Visiting Scientist at the Massachusetts Institute of Technology. Mr. Borland holds an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Materials Science and Engineering from the University of Arizona.
